Case opinion for PA Superior Court TIMOTHY STANGE v. JANSSEN PHARMACEUTICALS INC JOHNSON JOHNSON JANSSEN RESEARCH ... All of the cases in this mass tort involve male plaintiffs who allege they developed gynecomastia ...
Case opinion for PA Superior Court NICHOLAS MURRAY v. JANSSEN PHARMACEUTICALS INC JOHNSON JOHNSON JANSSEN RESEARCH ... All of the cases in this mass tort action consist of male plaintiffs who allege they ...... 682, 42 U.S.C. § 201 et seq. and was approved or licensed; or is generally recognized as ...
Janssen Pharmaceutical N.V. et al, case number 2:16-cv-06997, from California Central Court. ... suit accusing Johnson & Johnson subsidiary Janssen Pharmaceutical NV of using unlawful marketing practices ... Janssen Pharmaceuticals, Inc.
Jul 14, 2016 ... Counsel for the defendants denied all liability. ... jury verdict summary, including counsel and expert information, here: A.Y. and Billie Ann Yount v. Janssen Pharmaceuticals, Inc., Johnson & Johnson Company, and Johnson ...
Nov 4, 2013 ... Camile McGowan and Judy Doetterl v. Janssen Pharmaceutica, Inc., et al., No. 05-4536, and United States of America, ex rel. Kurtis J. Barry v.
Walia v. The Veritas Healthcare Solutions L.L.C., NY et al. Date: December 23, 2014. Docket Number: 1: ..... GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. ... Inc. v. Janssen Biotech, Inc. et al ...... Biro v. Conde Nast et al
T-336-14, ViiV HEALTHCARE ULC, ViiV HEALTHCARE UK LTD. ET AL v. ... T- 365-14, NOVARTIS PHARMACEUTICALS CANADA INC. v. ..... T-919-14, JANSSEN INC. v. DR. ...... THE CONDÉ NAST PUBLICATIONS LIMITED, Trade Mark Opposition, 2014-12-08, Pullan Kammerloch Frohlinger; HARWOOD JONES, TROY;.
Brevet - Contrefaçon, 06, 10:00, 1h. T-1627-16, ELI LILLY CANADA INC. ET AL. v . MYLAN PHARMACEUTICALS ULC ..... T-353-18, JANSSEN INC. ET AL v. ...... IMM-1482-18, ENVER AUGUSTO LOSADA CONDE ET AL v MCI (CJ-Anglais)
... (Baptista, 2009; Minelli et al., 2010; Ma et al., 2011; Conde et al., 2012c). .... are nanoparticles composed of semiconductor materials from III-V or II-VI groups of ... to therapeutics and theranostic agents (Akerman et al., 2002; Smith et al., 2006; ..... commercialized by Nanosphere Inc., is based on this biosensing strategy.